INTACT2

The purpose of the INTACT-2 study is to test if two treatments – iron (infused into the veins) and a man-made version of a hormone normally produced by the body (recombinant EPO, given as an injection under the skin) – can successfully treat anaemia and improve physical aspects of health-related quality of life, in patients after they leave ICU.

INTACT2 LOGO

Chief Investigator: Dr David M Griffith

 

Number and location of participating sites / geographical scope (by region/ country): UK 25 sites

EudraCT number: N/A

ISRCTN number: ISRCTN20195735

 

Funder: NIHR / MRC Efficacy and Mechanism Evaluation

 

Start and End date

Of grant award: August 2024

Of recruitment: May 2025

 

Current Status: Open to Recruitment        

 

UK GDPR privacy statement: Information can be found in our Patient Information Sheets.
 

You can find out more about how we use your information:

Sponsor: ACCORD, Usher Building, The University of Edinburgh, 5-7 Little France Road, Edinburgh BioQuarter - Gate 3, Edinburgh EH16 4UX      http://accord.scot/ 
 

Chief Investigator: David M Griffith, Centre for Population Health Sciences, The Usher Institute, Usher Building, The University of Edinburgh
BioQuarter, Gate 5-7, 3 Little France Road, Edinburgh, EH16 4UX 


Email: INTACT2.trial@ed.ac.uk
 

ECTU Involvement:  Trial management / Statistics / Health Economics / Database and randomisation service provision 

(UKCRC)

Co-enrolment between INTACT-2 and the following studies has been agreed: ABBRUPT, CAMELOT, CoReCCT - Awake Prone, NAVA, Protect airways and Release arms, ERASER, FRECyl-D, GenOMICC, GuARDS, IMPRoVE, INFINIT, MAP-ALF, MOSAICC, REMAP CAP, ROMEO, SepTIC, SHORTER, T4P, TraFFIC, TRAITS, AROMA-2, ASICS-II, BathMAT, REACT-SHOCK, VIKI and WISDOM

This article was published on